Navigation Links
Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer

se at the completion of combination therapy. Fifty of these patients received TELCYTA maintenance therapy and 50 did not receive maintenance therapy. Median progression-free survival for patients on TELCYTA maintenance therapy was 6.9 months, compared with 4.2 months for those who did not receive TELCYTA maintenance therapy (p< 0.0001, HR 0.36). Overall median survival for the TELCYTA-treated patients was 14.2 months compared with 8.4 months without TELCYTA maintenance therapy (p= 0.0003, HR 0.40).

The triplet combination was generally well-tolerated at all TELCYTA doses evaluated, with toxicities similar to those expected with each drug alone. There were no new, unexpected or cumulative toxicities. TELCYTA maintenance therapy was, as expected, well-tolerated, with Grade 1 or 2 toxicities observed in fewer than 5% of patients.

"Many approaches to maintenance therapy following first-line treatment for advanced non-small cell lung and ovarian cancer have been evaluated, with most adding little to efficacy while exposing patients to ongoing risks from toxic chemotherapy," said Gail L. Brown, M.D., senior vice president and chief medical officer. "The safety profile and clinical activity of TELCYTA, both in combination with carboplatin and paclitaxel and as monotherapy, suggest a potential role for this investigational agent as part of first-line combination treatment and as single agent maintenance therapy of non-small cell lung cancer. We will review these results with our expert advisors to discuss plans to expeditiously advance the TELCYTA program toward registration."

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung can
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Telcyta Clinical and Preclinical Presentations at AACR Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:7/29/2014)... , July 29, 2014  Encision Inc. (OTCQB:ECIA), a ... dangerous stray electrosurgical burns in minimally invasive surgery, today ... ended June 30, 2014. The Company posted ... net loss of $202 thousand, or $(0.02) per share. ... for a net loss of $311 thousand, or $(0.04) ...
(Date:7/29/2014)... , Next phase of ... has commenced , TPM®/Oxycodone Phase 2a trial ... 2014 , TPM®/Oxymorphone Phase 2 trial to ... Australian drug delivery company, Phosphagenics Limited (ASX: ... programs after its recent announcement of a $19.2 million capital raising. ...
(Date:7/29/2014)...   Health 2.0 announces Bernard Tyson , ... Eric Topol , Patrick Soon-Shiong , and Samsung,s ... 8th Annual Fall Conference this coming Sept. 21-24 in ... 2.0 is set to host the very first Wearable Tech ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3
... Hospira, Inc. (NYSE: HSP ... announced positive results from a Phase I U.S. clinical ... renal (kidney) dysfunction who have anemia. Hospira,s trial met ... and distribution in the body, for Hospira,s EPO and ...
... 6, 2011 Omthera Pharmaceuticals, Inc., a privately-held emerging ... and Chief Executive Officer, will present at the Rodman ... 2011 at 2:25pm ET at the Waldorf Astoria Hotel ... Pharmaceuticals, Inc. Founded in 2008, Omthera ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:7/29/2014)... (PRWEB) July 29, 2014 According to an ... uterine fibroid was recently removed from a 52 year old ... woman, identified only as Latha, reportedly had no idea that ... had been experiencing fatigue and breathlessness for years, but did ... Kumaran Hospital in Chennai only discovered the massive uterine fibroid ...
(Date:7/29/2014)... Francisco, California (PRWEB) July 29, 2014 ... reach USD 9,542.3 million by 2020, growing at an ... to a new study by Grand View Research, Inc. ... of these devices by the geriatric population, along with ... some of the major drivers of this market. In ...
(Date:7/29/2014)... iFitDress.com, one of the most famous dress ... 2014 high low wedding dresses . Aside from that, ... at discounted prices, up to 68% off. All the company’s ... before August 05. , The company’s sales representative is ... dresses. In the new collection, there are numerous great gowns ...
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... of the peer-reviewed journal Lipids in Health and ... value—of Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ... according to SPINS scan data, the product was ... to other omega-3 products in the marketplace. The ...
Breaking Medicine News(10 mins):Health News:World’s Largest Uterine Fibroid Removed from Patient 2Health News:World’s Largest Uterine Fibroid Removed from Patient 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6Health News:2014 High Low Wedding Dresses Provided By iFitDress.com 2Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3
... release is available in French . , ... on possible links between cell phone use and brain ... collaborated on the Interphone International Study Group. Jack Siemiatycki, ... epidemiologist at the University of Montreal Hospital Research Center, ...
... HACKENSACK, N.J. (May 17, 2010) John Theurer Cancer Center ... is one of two cancer centers in the tri-state ... DVS (Dose Verification System). John Theurer Cancer Center radiation ... the precise amount of radiation being delivered to tumors ...
... could pave way for tests that predict the illness, researchers ... of serious lung disease in middle age may have genetic ... history of such illnesses in their background, a new study ... might enable doctors to screen for genetic predispositions to serious ...
... ... in the May 17 – 21 event , ... (PRWEB) May 17, 2010 -- Pedego® Electric Bicycles has ... throughout Northern California, has added the Pedego Comfort Cruiser line of electric bikes to ...
... ... keep Affiliates informed on how to achieve the highest conversion performance. , ... Encino, CA (PRWEB) May 14, ... technology concerning the affiliate marketing industry. Founded in 2006, T3Leads has since provided unparalleled ...
... ... Patients Reverse Sun Damage and Restore the Health of Their Skin without Painful Surgery ... Los Angeles ... damage, resulting in wrinkles, sagging, age spots, discoloration and other unsightly symptoms. While a ...
Cached Medicine News:Health News:World's biggest study on cell phones and brain cancer inconclusive 2Health News:John Theurer Cancer Center offers breakthrough radiation measurement technology 2Health News:Lung Disease Can Be Genetic Even Without Family History 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 3Health News:Epione Reveals a &#8216;Bright' New Solution for Dull, Sun Damaged Skin 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: